- Home
- FLUX vs LEXX Comparison
FLUX vs LEXX Comparison
Compare FLUX & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLUX
- LEXX
- Stock Information
- Founded
- FLUX N/A
- LEXX 2004
- Country
- FLUX United States
- LEXX Canada
- Employees
- FLUX N/A
- LEXX N/A
- Industry
- FLUX Industrial Machinery/Components
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- FLUX Miscellaneous
- LEXX Health Care
- Exchange
- FLUX Nasdaq
- LEXX Nasdaq
- Market Cap
- FLUX 51.4M
- LEXX 49.3M
- IPO Year
- FLUX N/A
- LEXX N/A
- Fundamental
- Price
- FLUX $3.27
- LEXX $3.19
- Analyst Decision
- FLUX Strong Buy
- LEXX Strong Buy
- Analyst Count
- FLUX 4
- LEXX 2
- Target Price
- FLUX $9.50
- LEXX $11.00
- AVG Volume (30 Days)
- FLUX 73.2K
- LEXX 100.1K
- Earning Date
- FLUX 11-07-2024
- LEXX 11-18-2024
- Dividend Yield
- FLUX N/A
- LEXX N/A
- EPS Growth
- FLUX N/A
- LEXX N/A
- EPS
- FLUX N/A
- LEXX N/A
- Revenue
- FLUX $63,850,000.00
- LEXX $411,019.00
- Revenue This Year
- FLUX N/A
- LEXX $82.02
- Revenue Next Year
- FLUX $13.51
- LEXX $95.09
- P/E Ratio
- FLUX N/A
- LEXX N/A
- Revenue Growth
- FLUX N/A
- LEXX 34.05
- 52 Week Low
- FLUX $2.64
- LEXX $0.85
- 52 Week High
- FLUX $5.86
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- FLUX 55.59
- LEXX 48.73
- Support Level
- FLUX $2.85
- LEXX $2.91
- Resistance Level
- FLUX $3.19
- LEXX $3.39
- Average True Range (ATR)
- FLUX 0.21
- LEXX 0.20
- MACD
- FLUX 0.02
- LEXX 0.00
- Stochastic Oscillator
- FLUX 77.56
- LEXX 56.00
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.